Trial Profile
A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs Ieramilimab (Primary) ; Spartalizumab (Primary)
- Indications Advanced breast cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 20 Jan 2021 This trial has been discontinued in Germany (Global End Date: 31 Dec 2020), according to European Clinical Trials Database record.
- 19 Jan 2021 Status changed from active, no longer recruiting to completed.
- 10 Aug 2020 Planned End Date changed from 22 Jul 2020 to 23 Nov 2020.